Todos os estudos
RecrutamentoFASE2, FASE3INTERVENCIONISTA

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

This research is looking into a new treatment called KYV-101 for adults living with generalized myasthenia gravis, a condition that causes muscle weakness. Myasthenia gravis is an autoimmune disease, meaning the body's immune system mistakenly attacks healthy tissues, in this case, parts of the muscles. The new treatment, KYV-101, is a type of cell therapy that works by targeting and removing specific immune cells called B cells, which are thought to play a role in causing myasthenia gravis. The study aims to find out if KYV-101 is safe and effective in reducing the symptoms of muscle weakness and improving the overall quality of life for those with the condition. It’s a significant step towards finding new ways to manage this challenging disease.

Em resumo

Status
Recrutamento
Fase
FASE2, FASE3
Patrocinador
Kyverna Therapeutics
Meta de inscrição
66
Iniciar
28 Aug 2024
Conclusão estimada
01 Set 2028

Sobre o que é este estudo?

Myasthenia gravis is a long-term condition where your muscles become weak and tired easily because your immune system mistakenly attacks the connections between your nerves and muscles. This can make everyday tasks like walking, talking, or even smiling difficult. While there are treatments available, they don't work for everyone, and some people still experience significant challenges.

This study is exploring a new type of treatment called KYV-101, which is a cell therapy. Think of it as retraining your body's own defense system. The treatment specifically targets and removes certain immune cells, called B cells, which are believed to be heavily involved in causing myasthenia gravis. By getting rid of these problematic B cells, the hope is to reduce the immune system's attack on your muscles and lessen your symptoms.

The researchers want to see if KYV-101 can safely and effectively improve muscle strength and overall well-being for people living with generalized myasthenia gravis. This research is important because it could offer a new option for patients who haven't found enough relief from current treatments. It’s about finding better ways to help people regain more control over their daily lives.

Pontos principais

  • This study is testing a new cell therapy (KYV-101) for generalized myasthenia gravis.
  • The therapy aims to reduce muscle weakness by targeting specific immune cells.
  • It's for adults aged 18-75 who haven't fully responded to other treatments.
  • Participation involves ongoing monitoring and clinic visits.
  • The study could provide a new treatment option for myasthenia gravis.
  • Você pode se retirar do estudo a qualquer momento.

Quem pode ser elegível?

This study is looking for adults aged 18 to 75 who have been diagnosed with generalized myasthenia gravis. To be considered, you would need to have specific antibodies in your blood related to myasthenia gravis, and your muscle weakness should be at a certain level according to standard medical tests.

You would also need to have tried and not fully responded to at least two other common treatments for myasthenia gravis, or one treatment if you regularly need procedures like plasma exchange or IVIG to manage your symptoms. Your current medications for myasthenia gravis should also be at a stable dose for a certain period before joining.

There are also some reasons why you might not be able to join. For example, if you have other serious neurological conditions, an uncontrolled mental health illness, or certain other medical problems that the doctors think would make participating unsafe or complicate the study's results, you might not be eligible.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem entre 18 e 75 anos?
  2. Have you been diagnosed with generalized myasthenia gravis?
  3. Have you tried at least two other common myasthenia gravis treatments that weren't fully effective?
  4. Você consegue comparecer a consultas regulares na clínica?
  5. Do you have the specific antibodies related to myasthenia gravis in your blood?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part, you would have several visits to the study clinic for check-ups and assessments. The main treatment involves a special process where some of your immune cells (T-cells) are collected, sent away to be modified to become KYV-101, and then given back to you as an infusion. Before this, you might receive some short-term treatment to prepare your body.

Throughout the study, you'd have regular blood tests, physical examinations, and assessments of your muscle strength and daily activities to see how the treatment is affecting you. The total duration of your participation would involve the treatment period and then regular follow-up visits to monitor your health and the treatment’s effects. You’ll be told the exact schedule of visits and procedures if you are interested in joining.

Riscos e benefícios potenciais

Participating in any clinical trial has potential benefits and risks. You might benefit from a new treatment that could improve your myasthenia gravis symptoms, and you'd be contributing to medical research that could help others in the future. However, there are potential risks, as KYV-101 is an experimental treatment, and its side effects are still being fully understood. These could include reactions from the cell infusion or effects on your immune system. Doctors will carefully monitor you for any problems. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Localizações (22)

  • Ronald Reagan UCLA Medical Center
    Código postal verificado
    Los Angeles, Estados Unidos· Recrutamento
  • University of California, Irvine
    Código postal verificado
    Orange, Estados Unidos· Recrutamento
  • Stanford University Medical Center
    Código postal verificado
    Palo Alto, Estados Unidos· Recrutamento
  • Universidade de Miami
    Código postal verificado
    Miami, Estados Unidos· Recrutamento
  • Indiana University Health
    Código postal verificado
    Indianápolis, Estados Unidos· Recrutamento
  • University of Missouri
    Código postal verificado
    Columbia, Estados Unidos· Recrutamento
  • Oregon Health & Science University
    Código postal verificado
    Portland, Estados Unidos· Recrutamento
  • Thomas Jefferson University Hospital
    Código postal verificado
    Filadélfia, Estados Unidos· Recrutamento
  • Houston Methodist Hospital
    Código postal verificado
    Houston, Estados Unidos· Recrutamento
  • Intermountain Medical Center
    Código postal verificado
    Murray, United States· Recrutamento
  • Westmead Institute for Medical Research
    Código postal verificado
    Westmead, Australia· Recrutamento
  • Hospital Israelita Albert Einstein
    Código postal verificado
    São Paulo, Brazil· Recrutamento

Perguntas frequentes

What is generalized myasthenia gravis?

It's a long-term condition that causes muscle weakness and tiredness due to your immune system attacking the connections between nerves and muscles.

What is KYV-101?

It's a new type of cell therapy that works by targeting and removing specific immune cells called B cells, which are involved in myasthenia gravis.

How is KYV-101 given?

Your own immune cells are collected, modified, and then given back to you as an infusion (like a drip).

Will I still take my regular myasthenia gravis medication?

You'll need to be on stable doses of your current medications for a period before the study, and your doctors will advise on any changes during the trial.

What are the phases of this study?

This study is in Phase 2 and Phase 3, meaning it's still testing the safety and effectiveness of the new treatment in larger groups of people.

Como saber mais

Kyverna Therapeutics, Inc.

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cel…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.